⌕
Immatics · IMTX · Nasdaq
Tenet — · insufficient data
Compare
$6.17−3.44%At close
$6.17−0.22 (−3.44%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Immatics (IMTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 10, 2026 · 09:15 ET
Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates

Immatics (IMTX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.49 per share a year ago.…

● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Immatics Announces Third Quarter 2026 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, November 10, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell …

● Zacks Investment ResearchNov 9, 2026 · 11:01 ET
Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● GlobeNewsWireOct 24, 2026 · 02:30 ETCOMPANY'S OWN WORDS
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell t…

DW
● Defense WorldOct 9, 2026 · 04:46 ET
Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast

Kyntra Bio (NASDAQ: KYNB - Get Free Report) and Immatics (NASDAQ: IMTX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the stre…

● Defense WorldOct 9, 2026 · 04:33 ET
Immatics (NASDAQ:IMTX) Reaches New 1-Year Low – Here’s Why

Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $7.02 and last traded at $7.37, with a volume of 604725 shares. The stoc…

● Defense WorldOct 2, 2026 · 06:21 ET
Immatics (NASDAQ:IMTX) Sees Strong Trading Volume – Still a Buy?

Immatics N.V. (NASDAQ: IMTX - Get Free Report) shares saw unusually-strong trading volume on Wednesday. 434,954 shares changed hands during trading, a decline of 11% from the previous session's volume of 491,095 shares. …

● Seeking AlphaAug 25, 2026 · 13:45 ET
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. IMTX's investment thesis centers on anzu-cel [IMA203], a PRAME-directed TCR therapy in phas…

● GlobeNewsWireAug 25, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Immatics Announces $150 Million Underwritten Offering

Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell th…

● GlobeNewsWireAug 18, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Immatics Announces Second Quarter 2026 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell th…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just IMTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.